The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Inclusion Criteria: * Subjects ≥18 years of age signing of informed consent; * A history of clinical ASCVD, which is defined as: acute coronary syndrome, or a history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic origin; * Clinical diagnosis of type 2 diabetes according to ADA/ CDA guidelines; * Subject on stable dose of maximally-tolerated statin therapy for ≥4 weeks prior to screening and LDL-c ≥70mg/dL. For subjects whose maximally tolerated dose of statin is no type or dose (i.e. determined to be statin intolerant by primary investigator), background lipid-lowering therapy is not required; * Fasting triglycerides ≤400mg/dL (4.52mmol/L) by central laboratory at screening; * Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures; * Abnormal urinary Albumin Creatinine Ratio (ACR) as defined by an ACR ≥2; * Subject tolerates screening placebo injection. Exclusion Criteria: * Personal or family history of hereditary muscular disorders; * NYHA III or IV heart failure, or last know left ventricular ejection fraction (LVEF) \<30%; * Uncontrolled serious cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 6 weeks pri…